ClinicalTrials.gg
TerminatedNCT02099539Updated Sep 26, 2024Results posted

QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 interventional study of N-803 in Relapsed or Refractory Multiple Myeloma, sponsored by Altor BioScience. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Altor BioScience (part of ImmunityBio, Inc.) · Phase 1, Interventional, and Treatment

Why this study was terminated
Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,355th of 1,901
19 · median 36
Started
2014
with 78 others
Phase 1
559 of 2,168
64 open now
Registered
1,104th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,355th largest by enrollment of the 1,901 interventional ones that give a count, is one of 79 that started in 2014, is one of 559 in phase 1, and was the 1,104th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.

Read the detailed description

The purpose of this study is to evaluate the safety, determine the Maximum Tolerated Dose (MTD) or the Minimum Efficacious Dose (MED) and characterize the immunogenicity and pharmacokinetic profile of N-803 in treated patients. The effect of N-803 on the peripheral absolute lymphocyte counts and white blood cell counts, the number and phenotype of peripheral blood T (total and subsets) and NK cells will be evaluated. The anti-tumor responses of N-803 will also be assessed in this trial.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

Keywords

  • absolute lymphocyte count
  • antitumor
  • cancer
  • immunotherapy
  • immunochemotherapy
  • interleukin-15
  • multiple myeloma
  • NK cell
  • refractory
  • relapsed
  • T cell
  • white blood cell count
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 19 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.

First submitted before Altor BioScience became part of ImmunityBio, Inc..

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

ENTRY CRITERIA:

DISEASE CHARACTERISTICS:

  • Confirmed diagnosis of multiple myeloma after treatment with at least two different previous regimens.

    • Refractory disease is defined as progressive disease while on therapy or progression within 60 days of therapy.
    • Progressive disease is defined by a 25% increase from the lowest response value in specified tests.
  • as defined by at least one of the following:

    • Serum M-protein ≥ 1g/dL (for IgG, IgM) or 0.5 g/dL (for IgA)
    • Urine M-protein ≥ 200mg/24hours
    • Serum free light chains ≥ 10 mg/dL and abnormal kappa/lambda ratio

PRIOR/CONCURRENT THERAPY:

  • No anti-myeloma treatments within 14 days before the start of study treatment.
  • Must have recovered from side effects of prior treatments.

PATIENT CHARACTERISTICS:

Performance Status

  • 0, 1, or 2

Bone Marrow Reserve

  • (AGC/ANC) ≥ 1000/uL
  • ≥ 30,000/uL
  • ≥ 8g/dL
  • Absolute lymphocytes ≥ 800/uL
  • Leukocytes ≥ 3,000/uL

Renal Function

  • (GFR) > 40mL/min or Serum creatinine ≤ 1.5 X

Hepatic Function

  • Total ≤ 2.0 X ULN
  • , ALT, ALP ≤ 3.0 X ULN, or ≤ 5.0 X ULN (if liver exist)
  • No positive Hep C serology or active Hep B infection

Cardiovascular

  • No congestive heart failure \< 6 months
  • No unstable angina pectoris \< 6 months
  • No myocardial infarction \< 6 months
  • No history of ventricular arrhythmias
  • No history of supraventricular arrhythmias
  • No Class > II CHF
  • No marked baseline prolongation of /QTc interval

Pulmonary

  • Normal clinical assessment of pulmonary function

Other

  • Negative serum pregnancy test if female and of
  • Women who are not pregnant or nursing
  • Subjects, both females and males, with must agree to use effective measures for the duration of the study
  • No known disease other than corrected hypothyroidism
  • No known prior organ allograft or transplantation
  • Not positive
  • No history or evidence of uncontrollable CNS disease
  • No psychiatric illness/social situation
  • No other illness that in the opinion of the investigator would exclude the subject from participating in the study
  • Must provide and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
  • No active systemic infection requiring parenteral antibiotic therapy
  • No on-going chronic systemic (>10 mg daily prednisone equivalent) use or other therapy (a history of mild asthma not requiring therapy is eligible). Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Cohort 1: N-803 - IV 1 ug/kg

    Biological: N-803

  • Experimental
    Cohort 2: N-803 - IV 3 ug/kg

    Biological: N-803

  • Experimental
    Cohort 3: N-803 - IV 6 ug/kg

    Biological: N-803

  • Experimental
    Cohort 4: N-803 - IV 10 ug/kg

    Biological: N-803

  • Experimental
    Cohort 5: N-803 - SQ 10 ug/kg

    Biological: N-803

  • Experimental
    Cohort 6: N-803 - SQ 15 ug/kg

    Biological: N-803

Interventions

  • BiologicalN-803

    Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles

07

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events

    For phase I - Number of Participants with Treatment Emergent Adverse Events that occur or worsen after the first dose of study treatment.

    Time frame: 24 weeks

  2. Disease Response Rate of Treated Patients

    CR- negative SIFE and UIFE, disappearance of any soft tissue plasmacytomas, and \< or = to 5% plasma cells in bone marrow VGPR - either + SIFE and UIFE and - SPEP and UPEP or reduction in serum M-protein \> or = to 90% and urine m-protein level \<100mg per 24h PR - if measurable serum an urine m-protein them reduction of serum m-protein by \>=50% and reduction in 24h urinary m protein by \>=90% or to \<200mg per 24h if unmeasurable serum and urine m-protein then \>= 50% decrease in the difference between involve and uninvolved FLC levels If unmeasurable serum and urine m-protein and serum FLC assay then \>= 50% reduction in plasma cells, provide baseline bone marrow plasma cell percentage was \>=30% In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required PD - defined via International Myeloma Working Group uniform response criteria: disease progression SD - not meeting criteria for CR, VGPR, PR or PD

    Time frame: Starts at Week 11 - 12 and Week 23 - 24

Secondary outcomes

  1. Characterization of the Pharmacokinetic Profile - Half-life (t½)

    Half-life (t½) - The period of time required for the concentration or amount of drug in the body to be reduced by one-half.

    Time frame: PK timepoint up to 72 hours +/- 6 hours

  2. Characterization of the Pharmacokinetic Profile - Time of the Observed Maximum Concentration (Tmax)

    time of the observed maximum concentration (Tmax)

    Time frame: PK timepoint up to 72 hours +/- 6 hours

  3. Characterization of the Pharmacokinetic Profile - Maximum Observed Concentration (Cmax)

    maximum observed concentration (Cmax)

    Time frame: PK timepoint up to 72 hours +/- 6 hours

  4. Characterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve

    Area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t). PK samples were obtained from the start of treatment until 72 hours. The AUC0-168 and AUC0-inf were calculated with noncompartmental pharmacokinetic analysis equations.

    Time frame: Samples were collected and the AUC was determined at 24 hours and at time t (last measurable concentration). The AUC was calculated for 168 hours and time to infinity.

  5. Characterization of the Pharmacokinetic Profile - Clearance (CL)

    Clearance (CL)

    Time frame: PK timepoint up to 72 hours +/- 6 hours

  6. Characterization of the Pharmacokinetic Profile - Vss Volume of Distribution at Steady State

    Vss Volume of distribution at steady state is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration

    Time frame: PK timepoint up to 72 hours +/- 6 hours

  7. Immunogenicity - Anti-drug Antibody (ADA)

    Number of patients with a positive Anti-drug Antibody (ADA) result

    Time frame: From Baseline up to Week 12

  8. Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Clearance (CL/F)

    Apparent (Extravascular) Clearance (CL/F)

    Time frame: PK timepoint up to 72 hours +/- 6 hours

  9. Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)

    Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration

    Time frame: PK timepoint up to 72 hours +/- 6 hours

08

Results

Posted Sep 26, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kgCohort 7: N-803 - SQ 20 ug/kg
Started3333430
Completed0101000
Not completed3232430
Withdrew: Progressive disease3221420
Withdrew: Adverse event0011000
Withdrew: Physician decision0000010

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events

For phase I - Number of Participants with Treatment Emergent Adverse Events that occur or worsen after the first dose of study treatment.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
Number of Participants With Treatment Emergent Adverse Events333343
PrimaryDisease Response Rate of Treated Patients

CR- negative SIFE and UIFE, disappearance of any soft tissue plasmacytomas, and \< or = to 5% plasma cells in bone marrow VGPR - either + SIFE and UIFE and - SPEP and UPEP or reduction in serum M-protein \> or = to 90% and urine m-protein level \<100mg per 24h PR - if measurable serum an urine m-protein them reduction of serum m-protein by \>=50% and reduction in 24h urinary m protein by \>=90% or to \<200mg per 24h if unmeasurable serum and urine m-protein then \>= 50% decrease in the difference between involve and uninvolved FLC levels If unmeasurable serum and urine m-protein and serum FLC assay then \>= 50% reduction in plasma cells, provide baseline bone marrow plasma cell percentage was \>=30% In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required PD - defined via International Myeloma Working Group uniform response criteria: disease progression SD - not meeting criteria for CR, VGPR, PR or PD

Time frame:
Starts at Week 11 - 12 and Week 23 - 24
Reported as:
Count of participants · Participants
Disease Response Rate of Treated Patients
ParticipantsCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
Stable Disease011101
Progressive Disease321222
Not available to evaluate001010
SecondaryCharacterization of the Pharmacokinetic Profile - Half-life (t½)

Half-life (t½) - The period of time required for the concentration or amount of drug in the body to be reduced by one-half.

Time frame:
PK timepoint up to 72 hours +/- 6 hours
Reported as:
Mean · Hours
Characterization of the Pharmacokinetic Profile - Half-life (t½)
HoursCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
Characterization of the Pharmacokinetic Profile - Half-life (t½)0.773 (0.734 to 0.826)2.41 (2.40 to 2.41)2.21 (2.02 to 2.39)3.07 (2.33 to 4.14)—35.3 (35.3 to 35.3)
SecondaryCharacterization of the Pharmacokinetic Profile - Time of the Observed Maximum Concentration (Tmax)

time of the observed maximum concentration (Tmax)

Time frame:
PK timepoint up to 72 hours +/- 6 hours
Reported as:
Median · Hours
Characterization of the Pharmacokinetic Profile - Time of the Observed Maximum Concentration (Tmax)
HoursCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
Characterization of the Pharmacokinetic Profile - Time of the Observed Maximum Concentration (Tmax)0.583 (0.5 to 0.683)0.583 (0.5 to 0.633)0.65 (0.633 to 0.717)0.667 (0.667 to 2.33)33.1 (4.22 to 65.9)6.0 (2.0 to 20.3)
SecondaryCharacterization of the Pharmacokinetic Profile - Maximum Observed Concentration (Cmax)

maximum observed concentration (Cmax)

Time frame:
PK timepoint up to 72 hours +/- 6 hours
Reported as:
Mean · ng/mL
Characterization of the Pharmacokinetic Profile - Maximum Observed Concentration (Cmax)
ng/mLCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
Characterization of the Pharmacokinetic Profile - Maximum Observed Concentration (Cmax)8.45 ± 1.7842.7 ± 1.76142 ± 26.6144 ± 70.70.383 ± 0.1111.69 ± 1.41
SecondaryCharacterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve

Area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t). PK samples were obtained from the start of treatment until 72 hours. The AUC0-168 and AUC0-inf were calculated with noncompartmental pharmacokinetic analysis equations.

Time frame:
Samples were collected and the AUC was determined at 24 hours and at time t (last measurable concentration). The AUC was calculated for 168 hours and time to infinity.
Reported as:
Mean · hr x ng/mL
Characterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve
hr x ng/mLCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
AUC0-t10.5 (7.58 to 13.7)129 (105 to 166)634 (439 to 845)808 (577 to 1200)13.6 (6.00 to 21.2)60.4 (9.61 to 135)
AUC0-2410.6 (7.62 to 13.8)141 (116 to 166)731 (618 to 845)811 (577 to 1220)5.01 (2.91 to 6.69)31.1 (11.7 to 65.5)
AUC0-16810.6 (7.62 to 13.8)141 (116 to 166)732 (618 to 846)813 (578 to 1220)—31.4 (31.4 to 31.4)
AUC0-inf10.6 (7.61 to 13.7)141 (116 to 166)732 (618 to 846)814 (578 to 1220)—32.5 (32.5 to 32.5)
SecondaryCharacterization of the Pharmacokinetic Profile - Clearance (CL)

Clearance (CL)

Time frame:
PK timepoint up to 72 hours +/- 6 hours
Reported as:
Mean · mL/hr/kg
Characterization of the Pharmacokinetic Profile - Clearance (CL)
mL/hr/kgCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kg
Characterization of the Pharmacokinetic Profile - Clearance (CL)99.9 (72.7 to 131)22.0 (18.1 to 25.9)8.4 (7.09 to 9.71)13.7 (8.20 to 17.3)
SecondaryCharacterization of the Pharmacokinetic Profile - Vss Volume of Distribution at Steady State

Vss Volume of distribution at steady state is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration

Time frame:
PK timepoint up to 72 hours +/- 6 hours
Reported as:
Mean · mL/kg
Characterization of the Pharmacokinetic Profile - Vss Volume of Distribution at Steady State
mL/kgCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kg
Characterization of the Pharmacokinetic Profile - Vss Volume of Distribution at Steady State126 (101 to 159)71.8 (65.9 to 77.8)34.0 (30.2 to 37.8)62.8 (39.0 to 78.0)
SecondaryImmunogenicity - Anti-drug Antibody (ADA)

Number of patients with a positive Anti-drug Antibody (ADA) result

Time frame:
From Baseline up to Week 12
Reported as:
Count of participants · Participants
Immunogenicity - Anti-drug Antibody (ADA)
ParticipantsCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
Immunogenicity - Anti-drug Antibody (ADA)000000
SecondaryCharacterization of the Pharmacokinetic Profile - Apparent (Extravascular) Clearance (CL/F)

Apparent (Extravascular) Clearance (CL/F)

Time frame:
PK timepoint up to 72 hours +/- 6 hours
Reported as:
Mean · mL/hr/kg
Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Clearance (CL/F)
mL/hr/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Clearance (CL/F)—462 (462 to 462)
SecondaryCharacterization of the Pharmacokinetic Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)

Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration

Time frame:
PK timepoint up to 72 hours +/- 6 hours
Reported as:
Mean · mL/kg
Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)
mL/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kg
Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)—23500 (23500 to 23500)

Adverse events

Collected over Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: N-803 - IV 1 ug/kg2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Cohort 2: N-803 - IV 3 ug/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Cohort 3: N-803 - IV 6 ug/kg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Cohort 4: N-803 - IV 10 ug/kg0/3 (0%)0/3 (0%)3/3 (100%)
Cohort 5: N-803 - SQ 10 ug/kg3/4 (75%)3/4 (75%)4/4 (100%)
Cohort 6: N-803 - SQ 15 ug/kg0/3 (0%)0/3 (0%)3/3 (100%)
Cohort 7: N-803 - SQ 20 ug/kg———
Most frequent serious events
Most frequent serious events
EventCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kgCohort 7: N-803 - SQ 20 ug/kg
Back painMusculoskeletal and connective tissue disorders0/31/30/30/33/40/3—
PyrexiaGeneral disorders2/30/30/30/31/40/3—
DehydrationMetabolism and nutrition disorders1/30/30/30/30/40/3—
AtaxiaNervous system disorders0/30/31/30/30/40/3—
Cardiac arrestCardiac disorders0/30/30/30/31/40/3—
HypercalcaemiaMetabolism and nutrition disorders0/30/30/30/31/40/3—
Pain in extremityMusculoskeletal and connective tissue disorders0/30/30/30/31/40/3—
Most frequent other events
Showing 10 of 90
Most frequent other events
EventCohort 1: N-803 - IV 1 ug/kgCohort 2: N-803 - IV 3 ug/kgCohort 3: N-803 - IV 6 ug/kgCohort 4: N-803 - IV 10 ug/kgCohort 5: N-803 - SQ 10 ug/kgCohort 6: N-803 - SQ 15 ug/kgCohort 7: N-803 - SQ 20 ug/kg
ChillsGeneral disorders0/33/30/32/31/42/3—
Injection site reactionGeneral disorders0/30/30/30/34/40/3—
PyrexiaGeneral disorders2/33/31/32/33/43/3—
Back painMusculoskeletal and connective tissue disorders0/31/30/30/34/40/3—
NauseaGastrointestinal disorders1/31/31/31/33/40/3—
Lymphocyte count decreasedInfections and infestations1/31/30/32/33/41/3—
AnaemiaBlood and lymphatic system disorders2/31/31/32/32/40/3—
ConstipationGastrointestinal disorders1/32/31/30/31/40/3—
FatigueGeneral disorders1/30/32/32/31/41/3—
HypersensitivityImmune system disorders0/30/30/30/30/42/3—

Baseline characteristics

Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects

Age, Continuous
Age, Continuous(years)Cohort 1: ALT-803 - IV 1 ug/kgCohort 2: ALT-803 - IV 3 ug/kgCohort 3: ALT-803 - IV 6 ug/kgCohort 4: ALT-803 - IV 10 ug/kgCohort 5: ALT-803 - SQ 10 ug/kgCohort 6: ALT-803 - SQ 15 ug/kgCohort 7: ALT-803 - SQ 20 ug/kgTotal
Mean71.7 ± 4.1659.3 ± 6.6663.7 ± 6.3561.7 ± 12.149.8 ± 22.6367.0 ± 5.0—61.5 ± 13.05
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: ALT-803 - IV 1 ug/kgCohort 2: ALT-803 - IV 3 ug/kgCohort 3: ALT-803 - IV 6 ug/kgCohort 4: ALT-803 - IV 10 ug/kgCohort 5: ALT-803 - SQ 10 ug/kgCohort 6: ALT-803 - SQ 15 ug/kgCohort 7: ALT-803 - SQ 20 ug/kgTotal
Female20320209
Male130141010
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: ALT-803 - IV 1 ug/kgCohort 2: ALT-803 - IV 3 ug/kgCohort 3: ALT-803 - IV 6 ug/kgCohort 4: ALT-803 - IV 10 ug/kgCohort 5: ALT-803 - SQ 10 ug/kgCohort 6: ALT-803 - SQ 15 ug/kgCohort 7: ALT-803 - SQ 20 ug/kgTotal
American Indian or Alaska Native00000000
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American00101002
White332333017
More than one race00000000
Unknown or Not Reported00000000
Patients with Relapsed or Refractory Multiple Myeloma
Patients with Relapsed or Refractory Multiple Myeloma(Participants)Cohort 1: ALT-803 - IV 1 ug/kgCohort 2: ALT-803 - IV 3 ug/kgCohort 3: ALT-803 - IV 6 ug/kgCohort 4: ALT-803 - IV 10 ug/kgCohort 5: ALT-803 - SQ 10 ug/kgCohort 6: ALT-803 - SQ 15 ug/kgCohort 7: ALT-803 - SQ 20 ug/kgTotal
Count of participants333343019
09

Study locations

4 sites
  • University of Minnesota Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Jun 2018, 44 months.

Results were first posted in Sep 2024, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2014
First posted
Mar 31, 2014
StartActual
Oct 6, 2014
Primary completionActual
Jun 19, 2018
CompletionActual
Jun 19, 2018
Results first posted
Sep 26, 2024
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02099539
Lead sponsor
Altor BioScience
Responsible party
Sponsor
First posted
Mar 31, 2014
Start date
Oct 6, 2014
Primary completion
Jun 19, 2018
Completion
Jun 19, 2018
Results posted
Sep 26, 2024
Last update
Sep 26, 2024

Study contacts

Hing C Wong, PhD
study chair · Altor BioScience

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion